Sai life sciences IPO details Today : Sai life sciences IPO details Today is Open on [.] 2024 and Close on [.] 2024. Sai life sciences IPO to Raise [.] shares (Approx ₹[.] Cr) via IPO. The Fresh issue of [.] shares (Approx ₹[.] Cr).
We are an innovator-focused, contract research, development, and manufacturing organization (“CRDMO”). We provide endto-end services across the drug discovery, development, and manufacturing value chain, for small molecule new chemical entities (“NCE”), to global pharmaceutical innovator companies and biotechnology firms.
We possess both (a) discovery /contract research (“CRO”) and (b) chemistry, manufacturing, and control (“CMC”) / contract development and manufacturing organization (“CDMO”) capabilities.
Our CRDMO platform provides multiple entry points for us to acquire customers in the intermediate stages of their new drug
discovery to commercialization journey.
We are also one of the few CRDMOs to have a unique delivery model of having research laboratories for discovery and development located near overseas innovation hubs at Watertown (Greater Boston, MA), United States (“US”) and Manchester, United Kingdom (“UK”), complemented by large-scale research laboratories and manufacturing facilities in cost competitive locations in India.
we served more than 280 innovator pharmaceutical companies, including 18 of the top 25 pharmaceutical companies (in terms of revenue for the calendar year 2023), across regulated markets, including the US, the UK, Europe and Japan.
we also provided CRO services to more than 60 customers on an ongoing basis, for their integrated drug discovery programs. As of March 31, 2024, our CDMO product portfolio included more than 150 innovator pharmaceutical products, including 38 products that were supplied for manufacturing of 28 commercial drugs.
We provide our services through our globally accredited manufacturing and R&D facilities with quality systems that are supported by a qualified pool of scientists, engineers, and other scientific staff.
Object of the Issue
- Repayment/prepayment, in full or part, of all or certain outstanding borrowings availed by our Company.
- General corporate purposes.
Our Company Promoters
- Kanumuri Ranga Raju.
- Krishnam Raju Kanumuri.
- Kanumuri Mytreyi.
- Sai Quest Syn Private Limited.
- Marigold Partners.
- Sunflower Partners.
- Tulip Partners.
- Lily Partners.
Qualitative Factors
- One of the largest integrated Indian CRDMOs in terms of revenue from operations for the Financial Year 2024, acting as a one-stop platform for discovery, development and manufacturing.
- CDMO platform with a diverse mix of commercial and under-development molecules.
- Strategic business investments with improving profitability metrics.
- Fast-growing, integrated Discovery capabilities with focus on biology, chemistry and DMPK services
- Long-standing relationship with a diverse base of existing and new customers.
- Modern R&D infrastructure with a differentiated delivery model and strong regulatory track-record.
- Experienced management team and Board supported by a qualified scientific talent pool
Comparison of accounting ratios with listed industry peers
- Divi’s Laboratories Limited.
- Suven Pharmaceuticals Limited.
- Syngene International Limited.
Sai life sciences Company Contact Details
Plot no. DS-7, IKP Knowledge Park
Turkapally Village, Shameerpet Mandal
Medchal-Malkajgiri District 500 078
Telangana, India
Contact Person: Runa Karan
Email: investors@sailife.com
Tel: +91 40 6815 6000
Webiste: www.sailife.com
Sai life sciences IPO Registrar
KFin Technologies Limited
Selenium, Tower B, Plot No- 31 and 32
Financial District, Nanakramguda, Serilingampally
Hyderabad 500 032
Telangana, India
Tel: +91 40 6716 2222
E-mail: sailifesciences.ipo@kfintech.com
Investor Grievance ID: einward.ris@kfintech.com
Website: www.kfintech.com
Contact Person: M. Murali Krishna
